Significant upregulation of CLDN5 was observed in the following five tumors: glioblastoma multiforme (GBM), brain lower-grade glioma (LGG), liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), and pheochromocytoma and paraganglioma (PCPG) (Figure 1A). Here, CLDN5 is linked to pheochromocytoma-paraganglioma.